ES2124321T3 - Produccion de pdgf-ab heterodimero con la ayuda de un sistema de vector bicistronico en celulas de mamiferos. - Google Patents

Produccion de pdgf-ab heterodimero con la ayuda de un sistema de vector bicistronico en celulas de mamiferos.

Info

Publication number
ES2124321T3
ES2124321T3 ES93919177T ES93919177T ES2124321T3 ES 2124321 T3 ES2124321 T3 ES 2124321T3 ES 93919177 T ES93919177 T ES 93919177T ES 93919177 T ES93919177 T ES 93919177T ES 2124321 T3 ES2124321 T3 ES 2124321T3
Authority
ES
Spain
Prior art keywords
mammalian cells
vector system
heterodimero
pdgf
aid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93919177T
Other languages
English (en)
Inventor
Wolfram Eichner
Volker Achterberg
Albrecht Dorschner
Wolfgang Meyer-Ingold
Heiko Mielke
Wilhelm Dirks
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helmholtz Zentrum fuer Infektionsforschung HZI GmbH
Beiersdorf AG
Original Assignee
Helmholtz Zentrum fuer Infektionsforschung HZI GmbH
Beiersdorf AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helmholtz Zentrum fuer Infektionsforschung HZI GmbH, Beiersdorf AG filed Critical Helmholtz Zentrum fuer Infektionsforschung HZI GmbH
Application granted granted Critical
Publication of ES2124321T3 publication Critical patent/ES2124321T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

LA INVENCION SE REFIERE A LA ELABORACION RECOMBINANTE DE PDGFAB EN CELULAS DE MAMIFEROS POR MEDIO DE UN SISTEMA DE VECTOR BICISTRONICO EN DONDE SE LOCALIZA UNA SECUENCIA IRES ENTRE EL PRIMER Y SEGUNDO CISTRON Y DONDE EL GEN DE CODIFICACION DE CADENA B SE LOCALIZA EN EL PRIMER CISTRON. LA UNIDAD DE EXPRESION DESCRITA PERMITE LA EXPRESION EQUIMOLAR DE CADENAS POLIPEPTIDAS A Y B.
ES93919177T 1992-08-27 1993-08-26 Produccion de pdgf-ab heterodimero con la ayuda de un sistema de vector bicistronico en celulas de mamiferos. Expired - Lifetime ES2124321T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4228457A DE4228457A1 (de) 1992-08-27 1992-08-27 Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen

Publications (1)

Publication Number Publication Date
ES2124321T3 true ES2124321T3 (es) 1999-02-01

Family

ID=6466527

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93919177T Expired - Lifetime ES2124321T3 (es) 1992-08-27 1993-08-26 Produccion de pdgf-ab heterodimero con la ayuda de un sistema de vector bicistronico en celulas de mamiferos.

Country Status (8)

Country Link
US (2) US5665567A (es)
EP (1) EP0658199B1 (es)
JP (1) JP3515111B2 (es)
AU (1) AU4953893A (es)
DE (2) DE4228457A1 (es)
DK (1) DK0658199T3 (es)
ES (1) ES2124321T3 (es)
WO (1) WO1994005786A1 (es)

Families Citing this family (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6605712B1 (en) * 1990-12-20 2003-08-12 Arch Development Corporation Gene transcription and ionizing radiation: methods and compositions
DE4228458A1 (de) * 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
DE19514310A1 (de) * 1995-04-18 1996-10-24 Univ Ludwigs Albert Vektoren zur Transfektion von eukaryotischen Zellen, deren Verwendung und damit transfizierte Zielzellen
US6613956B1 (en) * 1996-04-04 2003-09-02 Chiron Corporation PI 3-kinase fusion mutants and uses thereof
CA2268276A1 (en) * 1996-10-18 1998-04-30 Jeff Nordstrom Gene expression and delivery systems and uses
DE19701141C1 (de) * 1997-01-16 1998-04-09 Hoechst Ag Genkonstrukte für durch Proteasen aktivierbare Wirksubstanzen
FR2762615B1 (fr) 1997-04-28 1999-07-16 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes et vecteur le contenant
EP1129110B1 (en) * 1998-11-10 2009-12-09 Ludwig Institute For Cancer Research Platelet-derived growth factor d, dna coding therefor, and uses thereof
DE60041183D1 (de) 1999-05-06 2009-02-05 Univ Wake Forest Zusammensetzungen und methoden zur identifikation von antigenen, die eine immunantwort hervorrufen
CA2375106C (en) 1999-06-01 2014-08-19 Huda Y. Zoghbi Compositions and methods for the therapeutic use of an atonal-associated sequence for deafness, osteoarthritis, and abnormal cell proliferation
AU7769800A (en) * 1999-08-10 2001-03-05 Develogen Ag Fur Entwicklungsbiologische Forschung Gene transfer combination vectors, method for the production and utilization thereof
US7037715B2 (en) * 1999-10-15 2006-05-02 The Mclean Hospital Multimerized DBH enhancer domains
EP1226273A4 (en) * 1999-10-15 2003-01-02 Mclean Hospital Corp MULTIMERIZED ENHANCER DOMAINS OF DHB
AU2001271614B2 (en) 2000-07-03 2007-05-31 Catalent Pharma Solutions, Llc Host cells containing multiple integrating vectors
AU7025201A (en) * 2000-07-03 2002-01-14 Gala Design Inc Expression vectors
DE60134234D1 (de) * 2000-08-08 2008-07-10 Mgvs Ltd Nukleinsäurekonstrukte, damit transformierte vaskuläre zellen, pharmezeutische zusammensetzungen und verfahren zur induktion der angiogenese
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
US20040242523A1 (en) * 2003-03-06 2004-12-02 Ana-Farber Cancer Institue And The Univiersity Of Chicago Chemo-inducible cancer gene therapy
US8034791B2 (en) 2001-04-06 2011-10-11 The University Of Chicago Activation of Egr-1 promoter by DNA damaging chemotherapeutics
US20030082685A1 (en) * 2001-04-06 2003-05-01 WEICHSELBAUM Ralph R. Chemotherapeutic induction of egr-1 promoter activity
AU2002327412A1 (en) 2001-08-02 2003-02-17 Institut Clayton De La Recherche Methods and compositions relating to improved lentiviral vector production systems
WO2003023000A2 (en) * 2001-09-07 2003-03-20 Baylor College Of Medicine Linear dna fragments for gene expression
EP1438075A4 (en) 2001-10-02 2006-04-19 Inst Clayton De La Rech METHOD AND COMPOSITIONS ASSOCIATED WITH LENTIVIRAL VECTORS WITH LIMITED EXPRESSION AND ITS APPLICATIONS
WO2003033463A2 (en) 2001-10-19 2003-04-24 The Mclean Hospital Corporation Multimerized enhancer domains for cell-specific expression
CN100417419C (zh) 2001-10-26 2008-09-10 贝勒医学院 改变个体的瘦体重和骨特性的组合物和方法
AU2002353970A1 (en) * 2001-11-02 2003-05-19 Rice University Recycling system for manipulation of intracellular nadh availability
US20030157641A1 (en) * 2001-11-16 2003-08-21 Idec Pharmaceuticals Corporation Polycistronic expression of antibodies
MXPA04005713A (es) 2001-12-11 2005-06-06 Baylor College Medicine Complemento de la hormona de liberacion de la hormona de crecimiento para tratar sujetos cronicamente enfermos.
US20040038304A1 (en) 2002-03-28 2004-02-26 Gala Design, Inc. Antibody libraries
CN100340668C (zh) * 2002-04-26 2007-10-03 国家健康医学研究所 改进的嵌合糖蛋白和假型化慢病毒载体
JP2006508635A (ja) 2002-05-06 2006-03-16 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 治療用または診断用試薬を送達するためのターゲティングタンパク質
EP1578396A4 (en) 2002-08-12 2007-01-17 David Kirn METHODS AND COMPOSITIONS RELATING TO POXVIRUS AND CANCER
CN1759182A (zh) * 2002-11-22 2006-04-12 克雷顿研究院 调节基因的组合物和系统
CA2516320C (en) 2003-02-18 2015-05-26 Kevin Slawin Induced activation in dendritic cells
WO2004081040A2 (en) 2003-03-12 2004-09-23 Advisys, Inc. Insulin-like growth factor (igf-i) plasmid-mediated supplementation for therapeutic applications
TW200424214A (en) * 2003-04-21 2004-11-16 Advisys Inc Plasmid mediated GHRH supplementation for renal failures
CA2531698A1 (en) 2003-07-09 2005-01-27 Sentigen Biosciences, Inc. Method for assaying protein-protein interaction
US20070224615A1 (en) * 2003-07-09 2007-09-27 Invitrogen Corporation Methods for assaying protein-protein interactions
EP1711187B1 (en) 2003-12-31 2010-05-12 VGX Pharmaceuticals, LLC Reducing arthritis and lameness in subjects by growth hormone releasing hormone (ghrh) supplementation
US8101169B2 (en) * 2005-02-23 2012-01-24 The Board Of Trustees Of The Leland Stanford Junior University Ocular gene therapy using avalanche-mediated transfection
US7923251B2 (en) * 2005-02-23 2011-04-12 The Board Of Trustees Of The Leland Stanford Junior University Method and apparatus for avalanche-mediated transfer of agents into cells
EP2484774A3 (en) 2005-07-21 2012-11-14 Abbott Laboratories Multiple gene expression including sorf contructs and methods with polyproteins, pro-proteins, and proteolysis
US20070026012A1 (en) 2005-08-01 2007-02-01 Cornell Research Foundation, Inc. Compositions and methods for monitoring and altering protein folding and solubility
KR101772375B1 (ko) * 2005-09-07 2017-08-29 신라젠(주) Ｇｍ-ｃｓｆ를 발현하는 폭스바이러스를 사용한 전이성 및/또는 전신 파종성 암의 전신 치료법
US8980246B2 (en) 2005-09-07 2015-03-17 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus cancer therapy
EP2368570A3 (en) 2006-01-18 2012-05-02 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
EP2064229B1 (en) 2006-09-15 2015-08-12 Ottawa Hospital Research Institute Oncolytic rhabdovirus
WO2008049113A2 (en) 2006-10-19 2008-04-24 Baylor College Of Medicine Generating an immune response by inducing cd40 and pattern recognition receptors
KR20080084528A (ko) 2007-03-15 2008-09-19 제네렉스 바이오테라퓨틱스 인크. 종양살상형 백시니아 바이러스 암 치료
US8440461B2 (en) 2007-03-23 2013-05-14 Wisconsin Alumni Research Foundation Reprogramming somatic cells using retroviral vectors comprising Oct-4 and Sox2 genes
KR101588736B1 (ko) 2008-01-10 2016-01-26 리서치 디벨롭먼트 파운데이션 얼리키아 샤피엔시스에 대한 백신 및 진단제
US20110014624A1 (en) * 2008-03-12 2011-01-20 Wyeth Llc Methods For Identifying Cells Suitable For Large-Scale Production of Recombinant Proteins
JP5779090B2 (ja) 2008-04-09 2015-09-16 マックスサイト インコーポレーティッド 新規に単離された細胞の治療組成物の操作および送達
JP2011522540A (ja) 2008-06-04 2011-08-04 セルラー ダイナミクス インターナショナル， インコーポレイテッド 非ウイルスアプローチを用いたｉＰＳ細胞の産生のための方法
CN107988261A (zh) * 2008-08-12 2018-05-04 细胞动力国际有限公司 产生ips细胞的方法
CA2734325A1 (en) 2008-08-18 2010-02-25 University Of Maryland, Baltimore Derivatives of apf and methods of use
ES2840750T3 (es) 2008-09-22 2021-07-07 Baylor College Medicine Métodos y composiciones para generar una respuesta inmune induciendo CD40 y adaptadores del receptor de reconocimiento de patrones
US8209867B2 (en) * 2008-10-02 2012-07-03 The Gillette Company Shaving razors and cartridges
CA2739581A1 (en) 2008-10-06 2010-04-15 University Of Chicago Compositions and methods related to bacterial eap, emp, and/or adsa proteins
EP2414387B1 (en) 2009-04-03 2015-12-16 University Of Chicago Compositions and methods related to protein a (spa) variants
JP2012528599A (ja) 2009-06-05 2012-11-15 セルラー ダイナミクス インターナショナル， インコーポレイテッド リプログラミングｔ細胞および造血細胞
ES2848650T3 (es) 2009-09-14 2021-08-11 Sillajen Biotherapeutics Inc Terapia combinada contra el cáncer con virus vaccinia oncolítico
US20110150861A1 (en) * 2009-10-30 2011-06-23 Abbott Laboratories Sorf constructs and multiple gene expression
MX337062B (es) 2009-12-10 2016-02-11 Ottawa Hospital Res Inst Rabdovirus oncolítico.
US10080799B2 (en) 2010-02-12 2018-09-25 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions related to glycoprotein-immunoglobulin fusions
EP2548030B1 (en) 2010-03-18 2015-05-27 Cornell University Engineering correctly folded antibodies using inner membrane display of twin-arginine translocation intermediates
US8808699B2 (en) 2010-04-05 2014-08-19 The University Of Chicago Compositions and methods related to protein A (SpA) antibodies as an enhancer of immune response
US8785385B2 (en) 2010-04-19 2014-07-22 Research Development Foundation RTEF-1 variants and uses thereof
WO2011146862A1 (en) 2010-05-21 2011-11-24 Bellicum Pharmaceuticals, Inc. Methods for inducing selective apoptosis
EP2582793B1 (en) 2010-06-15 2017-09-06 Cellular Dynamics International, Inc. A compendium of ready-built stem cell models for interrogation of biological response
CN103003416B (zh) 2010-06-15 2016-11-16 细胞动力学国际有限公司 从小体积的外周血产生诱导性多潜能干细胞
CN103037885B (zh) 2010-07-02 2015-08-26 芝加哥大学 与蛋白A(SpA)变体相关的组合物和方法
EP2591093B1 (en) 2010-07-07 2018-11-28 FUJIFILM Cellular Dynamics, Inc. Endothelial cell production by programming
CA2806858C (en) 2010-08-04 2021-06-15 Cellular Dynamics International, Inc. Reprogramming immortalized b cells
CA2810838C (en) 2010-09-08 2021-07-06 The Board Of Regents Of The University Of Texas System Somatostatin receptor-based cancer therapy
EP2614074A1 (en) 2010-09-09 2013-07-17 The University of Chicago Methods and compositions involving protective staphylococcal antigens
BR112013017096A2 (pt) 2011-01-04 2020-09-01 Jennerex Inc. composição e métodos de indução de resposta citotóxica dependente de complemento mediado por anticorpo específico de tumor em animal tendo tumor, de geração de anticorpos in vivo, de inibição do crescimento ou morte de célula de câncer, para tratar indivíduo com câncer, para adaptar de terapia de câncer para indivíduo com câncer e para identificar antígeno específico de tumor
WO2012098260A1 (en) 2011-01-21 2012-07-26 Axiogenesis Ag A non-viral system for the generation of induced pluripotent stem (ips) cells
US9574179B2 (en) 2011-02-08 2017-02-21 Cellular Dynamics International, Inc. Hematopoietic precursor cell production by programming
WO2012136653A1 (en) 2011-04-08 2012-10-11 Novvac Aps Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
US9364532B2 (en) 2011-06-08 2016-06-14 Children's Hospital Of Eastern Ontario Research Institute Inc. Compositions and methods for glioblastoma treatment
US20130040302A1 (en) 2011-07-11 2013-02-14 Thomas J. Burke Methods for cell reprogramming and genome engineering
US20130101664A1 (en) 2011-08-18 2013-04-25 Donald W. Kufe Muc1 ligand traps for use in treating cancers
WO2013053899A1 (en) 2011-10-12 2013-04-18 Moeller Niels Iversen Peptides derived from campylobacter jejuni and their use in vaccination
DK2809788T3 (da) 2012-02-02 2019-12-09 Univ Texas Adenovirusser der udtrykker heterologe tumor-associerede antigener
NZ702285A (en) 2012-04-26 2016-07-29 Univ Chicago Staphylococcal coagulase antigens and methods of their use
CA2874316A1 (en) 2012-05-03 2013-11-07 Indiana University Research And Technology Corporation Hydrodynamic methods for delivering fluids to kidney tissues and related materials and methods
US10125373B2 (en) 2013-01-22 2018-11-13 Arizona Board Of Regents On Behalf Of Arizona State University Geminiviral vector for expression of rituximab
CA2901501C (en) 2013-02-21 2023-03-07 Children's Hospital Of Eastern Ontario Research Institute Inc. Vaccine composition
CA2901747A1 (en) 2013-02-22 2014-08-28 Cellular Dynamics International, Inc. Hepatocyte production via forward programming by combined genetic and chemical engineering
WO2014132137A2 (en) 2013-03-01 2014-09-04 Université De Genève Transgenic cell selection
US9434935B2 (en) 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
KR20150131218A (ko) 2013-03-14 2015-11-24 벨리쿰 파마슈티컬스, 인크. T 세포 증식의 제어 방법
US20210332093A9 (en) 2013-04-11 2021-10-28 Vanderbilt University Fused in sarcoma (fus) nuclear translocation inhibitors for preventing fibrosis
ES2791598T3 (es) 2013-06-05 2020-11-05 Bellicum Pharmaceuticals Inc Métodos para inducir apoptosis parcial utilizando polipéptidos de caspasa
JP2016531147A (ja) 2013-09-09 2016-10-06 フィジーン、エルエルシーＦｉｇｅｎｅ， Ｌｌｃ コンドロサイトまたは軟骨型細胞の再生のための遺伝子治療
WO2015070050A1 (en) 2013-11-08 2015-05-14 Baylor Research Institute Nuclear loclization of glp-1 stimulates myocardial regeneration and reverses heart failure
CA2965327C (en) 2013-11-08 2023-05-09 The Board Of Regents Of The University Of Texas System Vh4 antibodies against gray matter neuron and astrocyte
EP3653714A1 (en) 2013-11-22 2020-05-20 DNAtrix, Inc. Adenovirus expressing immune cell stimulatory receptor agonist(s)
EP4227685A3 (en) 2013-12-03 2024-02-28 Evaxion Biotech A/S Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus
AU2015211034B2 (en) 2014-01-29 2020-04-09 Dana-Farber Cancer Institute, Inc. Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD)
EP3104866A4 (en) 2014-02-14 2017-08-02 Bellicum Pharmaceuticals, Inc. Methods for activating t cells using an inducible chimeric polypeptide
WO2015157636A1 (en) 2014-04-10 2015-10-15 H. Lee Moffitt Cancer Center And Research Institute, Inc. Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy
US20170107486A1 (en) 2014-04-21 2017-04-20 Cellular Dynamics International, Inc. Hepatocyte production via forward programming by combined genetic and chemical engineering
AU2015287833B2 (en) 2014-07-08 2018-09-13 The Children's Medical Center Corporation Compositions and methods for treating diabetes
US10888608B2 (en) 2014-09-02 2021-01-12 Bellicum Pharmaceuticals, Inc. Costimulation of chimeric antigen receptors by MyD88 and CD40 polypeptides
WO2016071758A1 (en) 2014-11-03 2016-05-12 Leiden University Medical Center T cell receptors directed against bob1 and uses thereof
US20180169211A1 (en) 2014-11-13 2018-06-21 Evaxion Biotech Aps Peptides derived from acinetobacter baumannii and their use in vaccination
CA2969145A1 (en) 2014-11-26 2016-06-02 The Regents Of The University Of California Therapeutic compositions comprising transcription factors and methods of making and using the same
JP6720176B2 (ja) 2014-12-15 2020-07-08 ベリカム ファーマシューティカルズ， インコーポレイテッド 治療用細胞のコントロールされた活性化または排除のための方法
WO2016113252A2 (en) 2015-01-12 2016-07-21 Evaxion Biotech Aps Proteins and nucleic acids useful in vaccines targeting klebsiella pneumoniae
WO2016134293A1 (en) 2015-02-20 2016-08-25 Baylor College Of Medicine p63 INACTIVATION FOR THE TREATMENT OF HEART FAILURE
CA2978171A1 (en) 2015-03-10 2016-09-15 J.H. Frederik Falkenburg T-cell receptors directed against the preferentially expressed antigen of melanoma and uses thereof
WO2017005670A1 (en) 2015-07-04 2017-01-12 Evaxion Biotech Aps Proteins and nucleic acids useful in vaccines targeting pseudomonas aeruginosa
CN108431211A (zh) 2015-10-20 2018-08-21 富士胶片细胞动力公司 通过遗传编程的多谱系造血前体细胞产生
US11246896B2 (en) 2015-10-28 2022-02-15 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Tumor-specific adenovirus vectors and therapeutic uses
CA3003145A1 (en) 2015-10-30 2017-05-04 Gay M. Crooks Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells
WO2017079202A1 (en) 2015-11-02 2017-05-11 Board Of Regents, The University Of Texas System Methods of cd40 activation and immune checkpoint blockade
US20190038713A1 (en) 2015-11-07 2019-02-07 Multivir Inc. Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
CA3004438A1 (en) 2015-11-09 2017-05-18 The Children's Hospital Of Philadelphia Glypican 2 as a cancer marker and therapeutic target
EP3419654B1 (en) 2016-02-22 2022-04-27 Evaxion Biotech A/S Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus
EP3436049B1 (en) 2016-03-31 2022-01-12 Baylor Research Institute Angiopoietin-like protein 8 (angptl8)
WO2017203057A1 (en) 2016-05-27 2017-11-30 Alk-Abelló A/S Immunogenic proteins and fragments thereof from allergenic mites
WO2017216384A1 (en) 2016-06-17 2017-12-21 Evaxion Biotech Aps Vaccination targeting ichthyophthirius multifiliis
WO2017220787A1 (en) 2016-06-24 2017-12-28 Evaxion Biotech Aps Vaccines against aearomonas salmonicida infection
US20180030478A1 (en) 2016-07-01 2018-02-01 Research Development Foundation Elimination of proliferating cells from stem cell-derived grafts
EP3889167A1 (en) 2016-07-22 2021-10-06 Evaxion Biotech ApS Chimeric proteins for inducing immunity towards infection with s. aureus
BR112019006910A2 (pt) 2016-10-05 2019-07-02 Fujifilm Cellular Dynamics Inc métodos para diferenciação dirigida de células-tronco pluripotentes para células imunes homozigóticas de hla
EP3538546A1 (en) 2016-11-14 2019-09-18 Novartis AG Compositions, methods, and therapeutic uses related to fusogenic protein minion
CN110381997A (zh) 2016-12-12 2019-10-25 茂体外尔公司 用于治疗和预防癌症和感染性疾病的包含病毒基因治疗和免疫检查点抑制剂的方法和组合物
JP2020504767A (ja) 2016-12-21 2020-02-13 メムゲン，エルエルシー 武装した複製可能な腫瘍溶解性アデノウイルス
US11298420B2 (en) 2016-12-21 2022-04-12 Memgen, Llc Armed oncolytic viruses
US11718648B2 (en) 2017-01-05 2023-08-08 Evaxion Biotech A/S Vaccines targeting Pseudomonas aeruginosa
WO2018185709A1 (en) 2017-04-05 2018-10-11 Centro De Neurociencias E Biologia Celular Compositions for reprogramming cells into dendritic cells or antigen presenting cells, methods and uses thereof
EP3385373A1 (en) 2017-04-05 2018-10-10 Centro de Neurociências e Biologia Celular Compositions for reprogramming cells into dendritic cells or antigen presenting cells, methods and uses thereof
EA201992469A1 (ru) 2017-04-18 2020-05-27 Фуджифилм Селльюлар Дайнамикс, Инк. Антигенспецифические иммунные эффекторные клетки
EP3621988A1 (en) 2017-05-09 2020-03-18 Bellicum Pharmaceuticals, Inc. Methods to augment or alter signal transduction
AU2018307877A1 (en) 2017-07-27 2020-01-02 Novartis Ag Sheddase resistant TREM2 variants
US11732029B2 (en) 2017-11-13 2023-08-22 The University Chicago Methods and compositions for the treatment of wounds
WO2019145399A1 (en) 2018-01-24 2019-08-01 Evaxion Biotech Aps Vaccines for prophylaxis of s. aureus infections
CA3094329A1 (en) 2018-03-19 2020-02-20 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer
US11413336B2 (en) 2018-03-23 2022-08-16 Board Of Regents, The University Of Texas System Coccidioides antigens and methods of their use
WO2019211320A1 (en) 2018-05-01 2019-11-07 Orfoneuro Aps Treatment of neuronal ceroid lipofuscinosis
SG11202102058UA (en) 2018-08-30 2021-03-30 Tenaya Therapeutics Inc Cardiac cell reprogramming with myocardin and ascl1
WO2020083904A1 (en) 2018-10-22 2020-04-30 Evaxion Biotech Aps Vaccines targeting m. catharrhalis
CN113710229A (zh) 2019-02-25 2021-11-26 芝加哥大学 用与抗炎剂连接的ecm亲和肽治疗炎症性和自身免疫性病症的方法和组合物
US20220143168A1 (en) 2019-02-27 2022-05-12 Evaxion Biotech A/S Vaccines targeting H. influenzae
WO2021007515A1 (en) 2019-07-11 2021-01-14 Tenaya Therapeutics, Inc. Cardiac cell reprogramming with micrornas and other factors
WO2021016062A1 (en) 2019-07-19 2021-01-28 The Children's Hospital Of Philadelphia Chimeric antigen receptors containing glypican 2 binding domains
US20220334129A1 (en) 2019-09-13 2022-10-20 Evaxion Biotech A/S Method for identifying T-cell epitopes
WO2021048381A1 (en) 2019-09-13 2021-03-18 Evaxion Biotech Aps Method for identifying stable mhc binding peptides using mass spectrometry
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
EP4087593A1 (en) 2020-01-06 2022-11-16 Evaxion Biotech A/S Vaccines targeting neisseria gonorrhoeae
BR112022017551A2 (pt) 2020-03-02 2022-11-16 Tenaya Therapeutics Inc Controle de vetor genético por micrornas expressos por cardiomiócito
JP2023520359A (ja) 2020-03-25 2023-05-17 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム 放射性核種イメージングのためのレポーター系
IL298085A (en) 2020-05-29 2023-01-01 Fujifilm Cellular Dynamics Inc Retinal pigment epithelium and bicellular photoreceptor aggregates and methods of using them
BR112022024064A2 (pt) 2020-05-29 2023-01-31 Fujifilm Cellular Dynamics Inc Bicamada de epitélio pigmentado da retina e fotorreceptores e uso dos mesmos
US11761020B2 (en) 2020-10-15 2023-09-19 Aavocyte, Inc. Recombinant adeno-associated virus vectors with CD14 promoter and use thereof
EP4291216A1 (en) 2021-02-09 2023-12-20 University of Houston System Oncolytic virus for systemic delivery and enhanced anti-tumor activities
KR20240005837A (ko) 2021-05-03 2024-01-12 아스텔라스 인스티튜트 포 리제너러티브 메디슨 성숙한 각막 내피 세포의 생성 방법
CA3217861A1 (en) 2021-05-07 2022-11-10 Astellas Institute For Regenerative Medicine Methods of generating mature hepatocytes
WO2022248531A1 (en) 2021-05-26 2022-12-01 Evaxion Biotech A/S Vaccination targeting intracellular pathogens
US20220389436A1 (en) 2021-05-26 2022-12-08 FUJIFILM Cellular Dynamics, Inc. Methods to prevent rapid silencing of genes in pluripotent stem cells
WO2023280807A1 (en) 2021-07-05 2023-01-12 Evaxion Biotech A/S Vaccines targeting neisseria gonorrhoeae
WO2023148398A1 (en) 2022-02-07 2023-08-10 Var2 Pharmaceuticals Aps Antibodies and antibody fragments and analogues specific for chondroitin sulfate
WO2023178191A1 (en) 2022-03-16 2023-09-21 University Of Houston System Persistent hsv gene delivery system
WO2023201207A1 (en) 2022-04-11 2023-10-19 Tenaya Therapeutics, Inc. Adeno-associated virus with engineered capsid
WO2023213393A1 (en) 2022-05-04 2023-11-09 Evaxion Biotech A/S Staphylococcal protein variants and truncates
WO2024006911A1 (en) 2022-06-29 2024-01-04 FUJIFILM Holdings America Corporation Ipsc-derived astrocytes and methods of use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5165938A (en) * 1984-11-29 1992-11-24 Regents Of The University Of Minnesota Wound healing agents derived from platelets
EP0259632B1 (en) * 1986-08-13 1995-12-13 Zymogenetics, Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US5358856A (en) * 1988-01-14 1994-10-25 Whitehead Institute For Biomedical Research Gene expression in mammalian cells using a cap independent 5' noncoding region
AU4036389A (en) * 1988-07-29 1990-03-05 Zymogenetics Inc. High efficiency translation of polycistronic messages in eucaryotic cells
US4902121A (en) * 1988-10-04 1990-02-20 Allergan Humphrey Range detector for eye instrument having interrogating beam
DE3834079A1 (de) * 1988-10-06 1990-04-12 Biotechnolog Forschung Gmbh Wachstumstimulierendes pdgf-bb und dessen verwendung sowie ein verfahren zu seiner herstellung und der des monomeren
DE3900770A1 (de) * 1989-01-12 1990-07-26 Juergen Prof Dr Hoppe Verfahren zur herstellung von pdgf-a und pdgf-aa
US5035887A (en) * 1989-09-07 1991-07-30 Institute Of Moelcular Biology, Inc. Wound healing composition of IL-1 and PDGF or IGF-1
IL96682A0 (en) * 1989-12-15 1991-09-16 Amgen Inc Production of biologically active platelet-derived growth factor from high expression host cell systems
US5149691A (en) * 1991-03-12 1992-09-22 Creative Biomolecules, Inc. Issue repair and regeneration through the use of platelet derived growth factor (pdgf) in combination with dexamethasone
JP3378962B2 (ja) * 1991-08-07 2003-02-17 アンダースン，ダブリュー．，フレンチ 内部リボソームエントリー部位を含むレトロウイルスベクター

Also Published As

Publication number Publication date
US5935819A (en) 1999-08-10
US5665567A (en) 1997-09-09
JPH08502884A (ja) 1996-04-02
AU4953893A (en) 1994-03-29
EP0658199B1 (de) 1998-10-21
DE4228457A1 (de) 1994-04-28
EP0658199A1 (de) 1995-06-21
DK0658199T3 (da) 1999-06-28
JP3515111B2 (ja) 2004-04-05
WO1994005786A1 (de) 1994-03-17
DE59309088D1 (de) 1998-11-26

Similar Documents

Publication Publication Date Title
ES2124321T3 (es) Produccion de pdgf-ab heterodimero con la ayuda de un sistema de vector bicistronico en celulas de mamiferos.
ES2114539T3 (es) Expresion de polipeptidos recombinados con purificacion mejorada.
TR199501134A2 (tr) Memeli ve viral proteinleri asiri ifade edilmesi.
NZ301858A (en) Expression of thrombopoietin
DK0929564T3 (da) Höjniveau-ekspression af proteiner
DK457587A (da) Fremgangsmaade til fremstilling af et protein af faktor viii:c-typen
FI960855A (fi) Monosyytti-makrofagisolulinjan yhdistelmäsoluja geeniterapiaa varten
GB1331285A (en) Optical mirrors
DK1222298T3 (da) Vektorer og fremgangsmåder til rekombinant proteinekspression
GT198302091A (es) Activador de plasminogeno de tejido humano a),b),c).
DK1137808T3 (da) Fremgangsmåde til fremstilling af rekombinante celler
ATE307890T1 (de) Prohormon-konvertase exprimierende polypeptid- synthese
DE3855504D1 (de) Rekombinante Herstellung von A-Ketten-Polypeptiden von PDGF
FI863430A0 (fi) Repressoituvat hiivapromoottorit
EP0270248A3 (en) Dna useful for the transport of foreign proteins to the plant cell wall
DK1025245T3 (da) Hurtig etablering af stabile pattedyrscelelinjer, der producerer höje koncentrationer af rekombinante proteiner
ES8800344A1 (es) Un metodo de produccion de actividad de isopenicilina n sintetasa en una celula huesped
TR200000288T2 (tr) İnsülin C-peptidin rekombinan ekspresyonu.
ATE218209T1 (de) In vitro multizellular test von angiogenesis
ES2141111T3 (es) Arnt sinteticos.
BR9708564A (pt) Polipeptídeo sequência de nucleotídeos vetor de express o célula hopedeira e processos para produzir uma subunidade alfa2 de prolil-4-hidroxilase e para produzir prolil-4-hidroxilase
ES2100953T3 (es) Expresion en lineas linfoblastoides humanas no tumorales con un vector integrante.
DK203588D0 (da) Fremgangsmaade til fremstilling af proteiner
FI885328A (fi) Foerfarande foer selektiv spaltning av fusionsproteiner.
ES2136199T3 (es) Expresion multicistronica de genes recombinantes en celulas bacterianas.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 658199

Country of ref document: ES